Scalper1 News
Drug giant Valeant Pharmaceuticals beat Q3 estimates and raised its guidance Monday, but the stock fell 7.7% as the CEO admitted that recent controversy over its high drug prices is leading to new strategies, including a possible sale of Valeant’s neurology business. On a conference call to discuss Q3 earnings Monday morning, Valeant (VRX) CEO J. Michael Pearson said the company will be adjusting its strategy in light of recent Scalper1 News
Scalper1 News